HopeStage
Back to all studies
TerminatedNCT02934932

A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD

Medication studyAges 18–65United States
The study in practice

Understand this study

Who could participate?

This study is for people with PTSD. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations
DurhamSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: April 25, 2017
Recruitment status
Terminated
Enrollment listed in the registry
15
Sponsor
Duke University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT02934932
Official title
Show the full official title

A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD

Recruitment & locations

Terminated

Durham

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Duke University, a university.

Does this study involve medication?

Yes. The study involves medication, including Brexpiprazole.

Who can participate?

This study is for people with PTSD. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies